Levonorgestrel intrauterine system (LNG-IUS) is used in patients with breast patients taking tamoxifen (TAM) to prevent endometrial proliferation. The benefits (on endometrium), the side effects (on breast), and the patients suitable for this treatment are not still clear. Aim of this systematic review is to define the breast risks and endometrial benefits in TAM-treated women using Mirena and to define which patients could benefit from LNG-IUS use. In all, 3 studies on LNG-IUS effects on endometrium in TAM-treated women and 4 studies on breast cancer recurrence were selected for the study. All studies described a reduction in benign endometrial pathologies among Mirena users, but controversial data showed malignant disease and breast cancer recurrence. So it is mandatory to define hormonal status before TAM treatment. In selected patients Mirena was proven to protect endometrium. Perspective clinical trials on Mirena pharmacological features are necessary to establish whether systemic levels of progesterone could increase breast cancer recurrence in such patients.
SiegelRWardEBrawleyOJemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236.
2.
BerryDACroninKAPlevritisSK. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–1792.
3.
AebiSDavidsonTGruberGCardosoF; ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(suppl 6):vi 12–vi 24.
4.
HammondMEHayesDFDowsettM. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
5.
DowsettMCuzickJIngleJ. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–518.
6.
ChinJKonjeJCHickeyM. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;(4):CD007245.
7.
American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol. 2006;107(6):1475–1478.
8.
MattsonL. Cost effectiveness in obstetrics and gynecology: the levonorgestrel intrauterine system. Minn Med. 2012;95(3):51–54.
9.
KiyotaniKMushirodaTNakamuraYZembutsuH. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet. 2012;27(1):122–131.
10.
LienEASolheimEUelandPM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51(18):4837–4844.
11.
OsborneCK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–1618.
12.
JensenEVJordanVC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980–1989.
LeeHJOrmandyCJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol. 2012;357(1-2):101–107.
15.
XuBKitawakiJKoshibaH. Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells. Maturitas. 2007;56(2):142–152.
16.
ObrAEEdwardsDP. The biology of progesterone receptor in thenormal mammary gland and in breast cancer. Mol Cell Endocrinol. 2012;357(1-2):4–17.
17.
GardnerFJKonjeJCAbramsKR. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000;356(9243):1711–1717.
18.
ChanSSTamWHYeoW. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG. 2007;114(12):1510–1515.
19.
KesimMDAydinYAtisAMandiraciG. Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric. 2008;11(3):252–257.
20.
BackmanTRauramoIJaakkolaK. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol. 2005;106(4):813–817.
21.
DingerJBardenheuerKMinhTD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211–217.
22.
TrinhXBTjalmaWAMakarAPBuytaertGWeylerJvan DamPA. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril. 2008;90(1):17–22.
23.
LyytinenHKDybaTYlikorkalaOPukkalaEI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well. Int J Cancer. 2010;126(2):483–489.
24.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), DaviesCGodwinJ. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784.
25.
BeversTBArmstrongDKArunB. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8(10):1112–1146.
26.
FisherBCostantinoJPWickerhamDL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–1662.
27.
FisherBCostantinoJPWickerhamDL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.
28.
WickerhamDLFisherBWolmarkN. Association of tamoxifen and uterine sarcoma. J Clin Oncol. 2002;20(11):2758–2760.
CadeTJQuinnMARomeRMNeeshamD. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7):879–884.
31.
HahnHSYoonSGHongJS. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19(6):1068–1073.
32.
KimMKYoonBSParkH. Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer. 2011;21(4):673–677.
33.
ShahMMWrightJD. Management of endometrial cancer in young women. Clin Obstet Gynecol. 2011;54(2):219–225.
34.
GallosIDShehmarMThangaratinamSPapapostolouTKCoomarasamyAGuptaJK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.e1–547 e10.
35.
EwiesAAAlfhailyF. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstet Gynecol Surv. 2012;67(11):726–733.
36.
MirkinSWongBCArcherDF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril. 2005;84(2):485–491.
37.
TrinhXBvan DamPATjalmaWA. Plasma concentrations of levonorgestrel in patients with an intrauterine progestogen delivery system: do they have any significance?Maturitas. 2006;55(1):94–95.
38.
WongAWChanSSYeoWYuMYTamWH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol. 2013;121(5):943–950.
39.
SaccardiCGizzoSPatrelliTS. Endometrial surveillance in Tamoxifen users: role, timing and accuracy of hysteroscopic investigation. Observational longitudinal cohort study. Endocr Relat Cancer. 2013;20(4):455–462.
40.
GizzoSSaccardiCPatrelliTS. Update on Raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013;68(6):467–481.
